comparemela.com
Home
Live Updates
Vaccitech Presents Interim Data from Phase 1b/2 Study of VTP-200 at 35th Annual International Papillomavirus Conference (IPVC) Highlighting Favorable Tolerability and Immunogenicity Profile : comparemela.com
Vaccitech Presents Interim Data from Phase 1b/2 Study of VTP-200 at 35th Annual International Papillomavirus Conference (IPVC) Highlighting Favorable Tolerability and Immunogenicity Profile
VTP-200 was generally well-tolerated and was administered with no product-related grade 3 unsolicited adverse events and no product-related serious adverse events in women with low grade human... | April 17, 2023
Related Keywords
Washington ,
United States ,
United Kingdom ,
American ,
Ifng Elispot ,
Jonothan Blackbourn ,
Kevin Gardner ,
Mike Beyer ,
Christopherm Calabrese ,
Meg Marshall ,
International Papillomavirus Conference ,
Nasdaq ,
Astrazeneca ,
American Cancer Society ,
Sam Brown Inc ,
Exchange Commission ,
University Of Oxford ,
Annual International Papillomavirus Conference ,
Chief Medical Officer ,
Private Securities Litigation Reform Act ,
Annual Report ,
Quarterly Reports ,
Cervical Cancer ,
Cancer Society ,
Key Statistics ,
Vaccitech Plc Stock Exchange ,
News ,
Information ,
Press Release ,
Gas ,
Igenerally ,
End ,
Administered ,
Ith ,
O ,
Rade ,
,
Unsolicited ,
Madverse ,
Events ,
Serious ,
N ,
Women ,
Dow ,
Rade Vacc Us91864c1071 ,
comparemela.com © 2020. All Rights Reserved.